Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.

HB 5050 (2025-2026)

https://ontology.bommaritollc.com/id/01a0d569-bdb8-732e-b6ff-5669cf547263

adms:identifier	mi-legislature-measure 2025-2026/HB/5050
dcterms:temporal	Michigan Legislature, 2025-2026 session
in committee	Senate Committee on Health Policy (2025-2026)
primary sponsor	Will Snyder
prov:wasDerivedFrom	evidence from https://www.legislature.mi.gov/Bills/Bill?ObjectName=2025-HB-5050 evidence from https://www.legislature.mi.gov/Bills/Bill?ObjectName=2025-HB-5050
schema:legislationChanges	MCL 333.17744a MCL 333.17744d
schema:legislationIdentifier	HB 5050
schema:legislationJurisdiction	Michigan
schema:legislationType	bill
schema:name	Health: pharmaceuticals; administration of epinephrine; modify. Amends secs. 17744a & 17744d of 1978 PA 368 (MCL 333.17744a & 333.17744d ). TIE BAR WITH: HB 5054'25 , HB 5049'25 , HB 5051'25 , HB 5052'25 , HB 5053'25en
schema:sponsor	Regina Weiss Mai Xiong Jason M Hoskins Morgan Foreman Nancy Jenkins-Arno Steve Frisbie Kathy Schmaltz Brenda Carter Mark A Tisdel Thomas Kuhn Alicia St. Germaine Joseph Pavlov Brian BeGole Penelope Tsernoglou Nancy DeBoer Will Snyder Luke Meerman Matthew Bierlein David Prestin Karl Bohnak
schema:url	https://www.legislature.mi.gov/Bills/Bill?ObjectName=2025-HB-5050
skos:prefLabel	HB 5050 (2025-2026)en
status	in committee
status date	2026-01-14xsd:date